TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Zentek ( (TSE:ZEN) ) just unveiled an update.
Zentek Ltd. announced the successful voting results from its annual and special meeting of shareholders, where all resolutions were approved, including the election of board members and the appointment of BDO Canada LLP as auditors. Notably, John Snisarenko was appointed as the new Chair of the Board, succeeding Eric Wallman. This leadership change is seen as a strategic move to support Zentek’s growth ambitions and enhance shareholder value as the company transitions its CEO and continues to develop its innovative technologies.
The most recent analyst rating on (TSE:ZEN) stock is a Hold with a C$1.50 price target. To see the full list of analyst forecasts on Zentek stock, see the TSE:ZEN Stock Forecast page.
Spark’s Take on TSE:ZEN Stock
According to Spark, TipRanks’ AI Analyst, TSE:ZEN is a Neutral.
Zentek’s overall stock score is primarily impacted by its weak financial performance, characterized by negative profitability and cash flow challenges. While technical analysis shows some neutral to slightly positive momentum, the valuation remains unattractive due to the negative P/E ratio. The absence of earnings call data and corporate events means these factors did not influence the score.
To see Spark’s full report on TSE:ZEN stock, click here.
More about Zentek
Zentek Ltd. is an ISO 13485:2016 certified intellectual property technology company focused on the research, development, and commercialization of novel products. The company aims to provide its commercial partners with a competitive advantage by enhancing their products to be better, safer, and greener. Zentek’s patented technology platform, ZenGUARD™, is known for its enhanced viral filtration efficiency for surgical masks and HVAC systems. Additionally, Zentek holds a global exclusive license for an Aptamer-based platform technology developed in collaboration with McMaster University for diagnostic and therapeutic markets.
Average Trading Volume: 58,106
Technical Sentiment Signal: Sell
Current Market Cap: C$124.6M
For a thorough assessment of ZEN stock, go to TipRanks’ Stock Analysis page.